Skip to main content

Table 2 Prognostic value of immune-cancer cell colocalization measures using univariate (white background) and multivariate (gray background) Cox regression in the discovery and validation cohorts for all breast cancers and Her2+ cancer defined by PAM50 and by SNP6

From: An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer

  Hazard ratio (95 % CI) P value Conc Hazard ratio (95 % CI) P value Conc
All breast cancers   Discovery cohort (475 samples) Validation cohort (514 samples)
Morisita 0.6 (0.42–0.86) 0.0052 0.56 0.41 (0.25–0.7) 0.00067 0.75
Lymphnode 2.36 (1.62–3.46) 9.4×10−6 0.607 3.55 (1.92–6.56) 5.4×10−5 0.73
Size 2.26 (1.63–3.13) 8.9×10−7 0.612 2.42 (1.57–3.73) 6.5×10−5 0.74
Grade 2.18 (1.59–3.01) 1.8×10−6 0.627 2.76 (1.66–4.59) 9.6×10−5 0.619
Morisita 0.59 (0.41–0.85) 0.005 0.699 0.4 (0.24–0.69) 0.00085 0.9
Lymphnode 1.78 (1.19–2.65) 0.0046 2.2 (1.16–4.17) 0.015
Size 1.89 (1.34–2.68) 0.00033 1.88 (1.17–3.03) 0.0096
Grade 1.82 (1.31–2.53) 0.00035 2.58 (1.53–4.34) 0.00038
Luminal A   Discovery cohort (150 samples) Validation cohort (178 samples)
Morisita 0.13 (0.04–0.45) 0.00014 0.715 0.29 (0.07–1.14) 0.059 0.618
Lymphnode 1.43 (0.46–4.42) 0.54 0.552 1.93 (0.5–7.47) 0.33 0.576
Size 4.38 (1.46–13.14) 0.0067 0.692 2.13 (0.69–6.62) 0.19 0.58
Grade 1.84 (0.83–4.1) 0.13 0.619 2.47 (0.9–6.79) 0.071 0.62
Morisita 0.15 (0.04–0.53) 0.003 0.839 0.33 (0.08–1.31) 0.11 0.733
Lymphnode 1.01 (0.3–3.41) 0.98   1.18 (0.29–4.8) 0.81  
Size 4.17 (0.99–17.56) 0.052   2.09 (0.54–8.14) 0.29  
Grade 1.44 (0.61–3.42) 0.41   2.47 (0.86–7.13) 0.095  
Her2 by PAM50   Discovery cohort (65 samples) Validation cohort (42 samples)
Morisita 0.29 (0.15–0.57) 0.00017 0.65 0.12 (0.02–0.61) 0.0022 0.808
Lymphnode 3.59 (1.55–8.3) 0.0015 0.64 NA 0.0098 0.666
Size 1.74 (0.97–3.12) 0.064 0.577 4.83 (1.48–15.78) 0.0051 0.689
Grade 1.68 (0.78–3.62) 0.18 0.574 0.29 (0.07–1.23) 0.075 0.529
Morisita 0.38 (0.17–0.84) 0.016 0.734 0.1 (0.01–0.66) 0.017 0.896
Lymphnode 2.2 (0.87–5.57) 0.095   NA 1  
Size 1.47 (0.83–2.61) 0.18   0.78 (0.16–3.83) 0.76  
Grade 1.8 (0.81–4.02) 0.15   0.37 (0.08–1.74) 0.21  
Her2+ by SNP6   Discovery cohort (72 samples) Validation cohort (56 samples)
Morisita 0.49 (0.25–0.98) 0.039 0.597 0.05 (0.01–0.4) 9.3×10 −5 0.808
Lymphnode 3.31 (1.5–7.31) 0.0017 0.637 7.31 (0.89–59.98) 0.031 0.666
Size 1.49 (0.82–2.73) 0.19 0.557 3.52 (1–12.36) 0.05 0.689
Grade 1.56 (0.68–3.59) 0.29 0.551 1.41 (0.36–5.58) 0.62 0.529
Morisita 0.44 (0.21–0.91) 0.027 0.722 0.03 (0–0.3) 0.0031 0.896
Lymphnode 3.68 (1.49–9.09) 0.0048   2.65 (0.28–24.99) 0.39  
Size 2.01 (1–4.04) 0.049   3.42 (1.1–10.64) 0.034  
Grade 1.46 (0.57–3.75) 0.43   1.86 (0.33–10.42) 0.48  
  1. Multivariate Cox regression includes lymph node status, tumor size, tumor grade, and the colocalization measure; age as a continuous or dichotomized variable using the optimal cutoff search was not associated with survival in all cancers or any subtype and hence was not considered. Bold text indicates significant p values for the newly proposed measures. Conc concordance, Her2+ human epidermal growth factor receptor 2-positive